The Latest Cardiac and Vascular News
EMERYVILLE, Calif.–(BUSINESS WIRE)–Fauna Bio, a biotechnology company improving human health by leveraging animal genomics, today announced Faun1083 as its first development candidate. Discovered through Fauna Bio’s proprietary Convergence™ drug discovery platform, Faun1083 is a potential first-in-class therapeutic targeting heart failure with preserved ejection fraction (HFpEF), a disease with currently limited […]
Partnerships with top institutions move leading candidates into pre-clinical evaluation; platform updates enable discovery of new targets EMERYVILLE, Calif., June 14, 2022 /PRNewswire/ — Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is […]
EMERYVILLE, Calif., May 4, 2022 /PRNewswire/ — Discovering new ways to treat heart and lung diseases by tapping into the natural disease resistance of hibernating animals is the focus of a new partnership between Monash University and Fauna Bio, a U.S. biotechnology company. Hibernation requires mechanisms of self-healing and tissue repair to endure […]
